• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Diabetes - Articles and news items

insulininjection

FDA approval for Sanofi’s Soliqua to treat type 2 Diabetes

Industry news / 29 November 2016 / Niamh Louise Marriott, Digital Editor

Soliqua 100/33 is the combination of Lantus (insulin glargine 100 Units/mL) and lixisenatide, a GLP-1 receptor agonist, studied in a Phase 3 program…

hyperglycaemia

Post-meal hyperglycaemia has negative impact on diabetic quality of life

Industry news / 4 November 2016 / Niamh Louise Marriott, Digital Content Producer

New data from a study related to post-meal or postprandial glucose control, show that poor PPG control has a negative impact on diabetics quality of life…

triple-therapy

NICE plans to recommend extra ‘triple therapy’ type 2 diabetes drug

Industry news / 7 October 2016 / Niamh Louise Marriott, Digital Content Producer

Once final guidance is published, dapagliflozin will join two other similar drugs, empagliflozin and canagliflozin, as options for triple therapy…

psoriasis-hands

Novartis’ global study shows 57% of psoriasis patients didn’t reach clear skin treatment goal

Industry news / 3 October 2016 / Niamh Louise Marriott, Digital Content Producer

People with the autoimmune disease, psoriasis, also report that they face discrimination, humiliation, and mental illness…

cover

Social media sourced Real World Evidence: A new wave in collecting data

Blog, Z Homepage promo / 3 October 2016 / Peter Brady, CEO Orbital Media and Dr Martin Goldman, independent medical officer, Iatros Consulting

Dr Martin Goldman joins Peter Brady, Orbital Media’s CEO, to discuss how to untap the potential of social media sourced real world evidence…

epr-logo

Novo Nordisk’s semaglutide reduced major cardiovascular events in 1 in 4 type 2 diabetic adults

Industry news / 21 September 2016 / Niamh Louise Marriott, Digital Content Producer

Fewer serious adverse events were seen with semaglutide vs placebo; however, treatment discontinuation due to adverse events was more frequent…

pass-new-coo

Gelesis appoints new Chief Operating Officer in anticipation of obesity product launch

Industry news / 6 September 2016 / Niamh Louise Marriott, Digital Content Producer

Gelesis, a biotechnology company focused on developing products to safely induce weight loss and improve glycaemic control, have appointed David Pass, PhD as Chief Operating Officer…

scotland nhs diabetes novo nordisk

NHS Scotland approves Novo Nordisk’s diabetes drug

Industry news / 9 August 2016 / Novo Nordisk

The drug was approved using evidence from three phase III studies in adults with type 1 diabetes mellitus and five phase III studies in adults with type 2 diabetes mellitus. The researchers discovered that insulin degludec was non-inferior to other long-acting insulin analogues, assessed by the mean change in glycosylated haemoglobin (HbA1c)…

Stem cell nano drug delivery applications to treat diabetes

Sanofi receives FDA approval of Adlyxin TM for treatment of adults with Type 2 Diabetes

Industry news / 28 July 2016 / Sanofi

U.S. Food and Drug Administration (FDA) have approved Sanofi’s Adlyxin TM (lixisenatide), a once-daily mealtime GLP-1 receptor agonist injection indicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes…

type 2 diabetes

Companies prioritise competitive pricing in type 2 diabetes, says GlobalData

Industry news / 6 July 2016 / Victoria White, Digital Content Producer

The type 2 diabetes market will see companies prioritisng competitive pricing in order to offset the impact of patent expiries, says GlobalData…

jardiance

Jardiance reduces risk of progressive kidney disease in type 2 diabetes

Industry news / 14 June 2016 / Victoria White, Digital Content Producer

Jardiance reduced the risk for new-onset or worsening kidney disease by 39% versus placebo in adults with type 2 diabetes with established CV disease…

type 2 diabetes

Ertugliflozin shows significant A1C reductions in type 2 diabetes

Industry news / 14 June 2016 / Victoria White, Digital Content Producer

Two studies of ertugliflozin, an investigational oral SGLT-2 inhibitor for the treatment of patients with type 2 diabetes, met their primary endpoints…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionWATCH NOW
+ +